Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 1700 • ACR Convergence 2021
Pharmacokinetic Boosting to Enable Once-Daily Reduced Dose Tofacitinib
Céleste van der Togt¹, Lise Verhoef², Nathan den Broeder³, Rob ter Heine³, Bart van den Bemt⁴ and Alfons den Broeder⁵, ¹Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands, ³Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands, ⁴Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, ⁵Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tofacitinib is an effective, yet costly, drug for treatment of RA and PsA. Tofacitinib is metabolized mainly by the cytochrome P450-enzyme CYP3A4, and the…
Abstract Number: 1830 • ACR Convergence 2021
Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Sophia Wolfe¹, Elizabeth Cheng², Kavya Ganuthula¹, Meika Fang³, Gail Kerr⁴, Jessica Walsh⁵, Elizabeth Chang⁶, Siba Raychaudhuri⁷, Kyle Brees², Robert Dellavalle¹, Andreas Reimold⁸ and Liron Caplan⁹, ¹Rocky Mountain Regional VAMC/University of Colorado School of Medicine, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³David Geffen School of Medicine at UCLA/West Los Angeles Veterans Affairs Medical Center (VAMC), Los Angeles, CA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ⁶Phoenix VAMC, Phoenix, AZ, ⁷Sacramento Veterans Affairs Medical Center (VAMC)/University of California-Davis Health, Davis, CA, ⁸University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁹Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease of the joints and skin that affects 1/1000 people in the US. Tumor necrosis factor-alpha (TNF-α)…
Abstract Number: 1939 • ACR Convergence 2021
Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study
Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus,…
Abstract Number: 2000 • ACR Convergence 2020
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Prior studies suggest an increased risk of venous thromboembolism (VTE) among patients with rheumatoid arthritis (RA). However, little is known about the comparative risk…
Abstract Number: 0534 • ACR Convergence 2020
National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use
Meghna Jani¹, Belay Yimer¹, Therese Sheppard¹, Mark Lunt¹ and William Dixon¹, ¹Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom
Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…
Abstract Number: 0550 • ACR Convergence 2020
Mapping Multimorbidity Using Drug Concept Unique Identifiers (RxCUIs) via the Rx-Risk Comorbidity Index
Jared Vanderbleek¹, Justin Owensby¹, Alex Mccannaly¹, Lang Chen¹, Bryant England², Jeffrey R Curtis³ and Huifeng Yun³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Identifying and accurately classifying comorbid conditions in large, real-world data sources is crucial for cohort establishment and confounder adjustment. However, the ability to conduct…
Abstract Number: 0594 • ACR Convergence 2020
Mechanical and Temperature Stress During Biologic Shipments to Rheumatology Patients
Sarah Dill¹, Elizabeth Cheng², Kyle Brees², John Carpenter³ and Liron Caplan², ¹University of Colorado, Denver, CO, ²Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO, ³University of Colorado Skaggs School of Pharmacy, Aurora, CO
Background/Purpose: Biologic medications are expensive, and unfortunately their immunogenicity contributes to loss of efficacy over time. Protein particles may form as a result of medication…
Abstract Number: 1122 • ACR Convergence 2020
Osteoarthritis in a Large Integrated Health System Population: 18-Year Retrospective Review
Jove Graham¹, Tonia Novosat¹, Haiyan Sun¹, Brian Piper², Joseph Boscarino¹, Melissa Kern¹, Vanessa Duboski³, Eric Wright³, Patricia Schepman⁴, Rebecca Robinson⁵, Edward Casey⁶, Craig Beck⁷ and Jerry Hall⁸, ¹Geisinger, Danville, ²Geisinger, Scranton, ³Geisinger, Forty Fort, ⁴Pfizer, New York City, NY, ⁵Eli Lilly and Company, Indianapolis, ⁶Pfizer, New York, ⁷Pfizer, London, ⁸Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Osteoarthritis (OA) is a mechanically and immunologically mediated common disease with a complex pathogenesis. Despite epidemiologic studies proving increasing age, obesity and female gender…
Abstract Number: 1481 • ACR Convergence 2020
A Systematic Review to Quantify the Extent of Pharmaceutical Company Involvement in Rheumatology Consensus-Based Recommendations
Dominique Feterman Jimenez¹, Garret Duron², Ali Duarte-Garcia³, Paul Sufka⁴, Samuel Whittle⁵, Philip Robinson⁶, Larry Prokop³ and Michael Putman⁷, ¹UConn Health Center, Farmington, CT, ²HCA Memorial Health University Medical Center, Savannah, GA, ³Mayo Clinic, Rochester, MN, ⁴Healthpartners, St Paul, ⁵Rheumatology Unit, The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁶University of Queensland, Herston, Queensland, Australia, ⁷Northwestern University, Chicago, IL
Background/Purpose: Consensus-based recommendations guide standards of care for clinical practice. Pharmaceutical-industry involvement in producing such recommendations may undermine their objectivity. We performed a systematic review…
Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Amy Cunningham-Bussel¹, Jiaqi Wang¹, Lauren C. Prisco², Lily Martin², Lydia Gedmintas¹, Lindsey Macfarlane¹, Nancy Shadick¹, Mark Awad³, Osama Rahma³, Nicole LeBoeuf³, Ellen Gravallese¹ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Dana-Farber Cancer Institute, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…
Abstract Number: 1637 • ACR Convergence 2020
Comparison of Nation-wide Epidemical Study on 2009 and That on 2019 Revealed That Improvement of Disease Severity and Mortality Rate May Come from Progress of Proficient Management in Patients with Relapsing Polychondritis in Japan
Jun Shimizu¹, Yoshihisa Yamano¹, Kimito Kawahata² and Noboru Suzuki¹, ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: We conducted a retrospective survey study in 2009 and collected clinical data of 239 patients with relapsing polychondritis (RP). Using the survey data, we…
Abstract Number: 1993 • ACR Convergence 2020
Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Mengdong He¹, Ajinkya Pawar¹, Rishi Desai¹, Robert Glynn¹, Hemin Lee¹, Michael Weinblatt¹, Daniel H Solomon¹ and Seoyoung Kim¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a known risk factor for cardiovascular (CV) events. While most RA patients use conventional disease-modifying antirheumatic drugs (DMARDs) such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].